Health-related quality of life for pembrolizumab (pembro) plus ipilimumab (ipi) versus pembro plus placebo in patients with metastatic NSCLC with PD-L1 tumor proportion score ? 50%: KEYNOTE-598.

Sendur, Mehmet NahitReck, MartinRodriguez-Abreu, DelvysPark, KeunchilLee, Dae HoCicin, IrfanYumuk, Perran Fulden2024-06-122024-06-1220210732-183X1527-7755https://doi.org/10.1200/JCO.2021.39.15_suppl.9038https://hdl.handle.net/20.500.14551/25940Virtual Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) -- JUN 04-08, 2021 -- ELECTR NETWORK[Abstract Not Available]en10.1200/JCO.2021.39.15_suppl.9038info:eu-repo/semantics/closedAccess[No Keywords]Health-related quality of life for pembrolizumab (pembro) plus ipilimumab (ipi) versus pembro plus placebo in patients with metastatic NSCLC with PD-L1 tumor proportion score ? 50%: KEYNOTE-598.Conference Object3915Q1WOS:000708120605019